Table 2.

Prevalence of Use of Medications Among Those Receiving Any or 1, 2, or 3 Medications for Diabetes (%)^a

	Metformin			Sulfonylureas (Short)			Sulfonylureas (Long)			Thiodolezinediones			Insulin			Other
	TM	MA	Diff	TM	MA	Diff	TM	MA	Diff	TM	MA	Diff	TM	MA	Diff	TM	MA	Diff
Overall	67.7	70.1	−2.5	19.7	23.6	−4.0	17.1	16.3	0.8	6.6	6.1	0.5	19.7	17.4	2.3	21.3	16.2	5.1
On One Medication	59.8	62.7	−2.9	8.8	10.8	−2.1	7.6	7.6	0.1+	2.0	1.7	0.2	15.1	12.6	2.5	6.8	4.5	2.2
On Two Medications	79.7	82.8	−3.2	31.5	39.6	−8.1	27.2	26.8	0.4	8.0	7.4	0.7	22.5	20.4	2.0	31.2	22.9	8.2
On Three Medications	91.1	91.9	−0.8	44.3	50.9	−6.5	41.8	38.3	3.5	25.9	27.7	−1.8	39.3	38.8	0.4+	70.8	64.4	6.4

^a.TM estimates are weighted to match MA distributions by age category, sex, race/ethnicity categories, and geography. Differences between TM and MA are statistically significant at the p<.0001 level, except for (+), which was <.01.

Other includes GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, Meglitinides, and D-Phenylalanine Derivatives. *TM estimates are weighted to match MA distributions by age category, sex, race/ethnicity categories, and geography. All overall MA-TM differences (first row) are statistically significant at p≤.001 except for LASU (p=.02) and insulin (p=.22). Significant differences by region, plan age, and plan size are noted by (+), signifying p<.01).

Other includes GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, Meglitinides, and D-Phenylalanine Derivatives.